Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

With the augmented data, binary classification was performed by gradient boosting decision trees to predict personalized survival distributions for each patient and provide explanations of individual risk factors using SHAP values.Summary statistics of the cohort based on the final feature set.LevelOverallCensoredDiedSurvivedn33,93814,907166217,369Age, median [Q1, Q3]49.0 [33.0,64.0]50.0 [34.0,66.0]83.0 [75.0,89.0]45.0 [31.0,59.0]Sex, n (%)Female19,581 (57.7)8800 (59.0)787 (47.4)9994 (57.5)Number of ordered medicines, median [Q1, Q3] n (%)0.0 [0.0,4.0]0.0 [0.0,4.0]16.0 [4.0,27.0]0.0 [0.0,2.0]020,207 (59.5)8854 (59.4)168 (10.1)11,185 (64.4)≥ 113,731 (40.5)6053 (40.6)1494 (89.9)6184 (35.6)Number of diagnoses, median [Q1, Q3] n (%)4.0 [2.0,8.0]4.0 [2.0,8.0]11.0 [6.0,16.0]4.0 [2.0,7.0]05596 (16.5)2277 (15.3)54 (3.2)3265 (18.8)≥ 128,342 (83.5)12,630 (84.7)1608 (96.8)14,104 (81.2)Admitted at the time of first positive test, n (%)2485 (7.3)927 (6.2)534 (32.1)1024 (5.9)Previous admissions in the last 3 years, median [Q1, Q3]0.0 [0.0,1.0]0.0 [0.0,1.0]1.0 [0.0,3.0]0.0 [0.0,0.0]Cumulative days in hospital within the last 3 years, median [Q1, Q3]0.0 [0.0,1.0]0.0 [0.0,1.0]7.0 [0.0,19.0]0.0 [0.0,0.0]Pandemic week, median [Q1, Q3]39.0 [19.0,42.0]42.0 [41.0,44.0]40.0 [7.0,43.0]26.0 [6.0,35.0]Body Mass Index, median [Q1, Q3]25.7 [22.6,29.7]25.6 [22.5,29.8]24.3 [21.3,28.0]26.0 [23.0,29.9]Absolute Lymphocyte count (LYM), laboratory, last value, median [Q1, Q3]1.1 [0.7,1.6]1.1 [0.8,1.7]0.9 [0.6,1.3]1.2 [0.8,1.6]Laxatives (A06AD), ordered medicine, count, n (%)031,131 (91.7)13,639 (91.5)919 (55.3)16,573 (95.4)≥ 12807 (8.3)1268 (8.5)743 (44.7)796 (4.6)Paracetamol (N02BE), ordered medicine, count, n (%)026,453 (77.9)11,430 (76.7)527 (31.7)14,496 (83.5)≥ 17485 (22.1)3477 (23.3)1135 (68.3)2873 (16.5)Loop diuretics (C03CA), ordered medicine, count, n (%)031,403 (92.5)13,753 (92.3)965 (58.1)16,685 (96.1)≥ 12535 (7.5)1154 (7.7)697 (41.9)684 (3.9)Opioid anesthetics (N01AH), ordered medicine, count, n (%)030,920 (91.1)13,470 (90.4)1314 (79.1)16,136 (92.9)≥ 13018 (8.9)1437 (9.6)348 (20.9)1233 (7.1)Vitamin B-complex (A11EA), ordered medicine, count, n (%)033,216 (97.9)14,515 (97.4)1497 (90.1)17,204 (99.1)≥ 1722 (2.1)392 (2.6)165 (9.9)165 (0.9)Alzheimer's disease (G30), diagnose, count, n (%)033,432 (98.5)14,655 (98.3)1529 (92.0)17,248 (99.3)≥ 1506 (1.5)252 (1.7)133 (8.0)121 (0.7)Encounter for medical observation (Z03), diagnose, count, n (%)024,170 (71.2)10,568 (70.9)788 (47.4)12,814 (73.8)≥ 19768 (28.8)4339 (29.1)874 (52.6)4555 (26.2)Encounter for other special examination (Z01), diagnose, count, n (%)018,284 (53.9)7485 (50.2)637 (38.3)10,162 (58.5)≥ 115,654 (46.1)7422 (49.8)1025 (61.7)7207 (41.5)Essential hypertension (I10), diagnose, count, n (%)031,501 (92.8)13,783 (92.5)1256 (75.6)16,462 (94.8)≥ 12437 (7.2)1124 (7.5)406 (24.4)907 (5.2)Loop diuretics (C03CA), administered medicine, count, n (%)032,384 (95.4)14,135 (94.8)1177 (70.8)17,072 (98.3)≥ 11554 (4.6)772 (5.2)485 (29.2)297 (1.7)Calcium + vitamin D (A12AX), administered medicine, count, n (%)032,530 (95.9)14,200 (95.3)1267 (76.2)17,063 (98.2)≥ 11408 (4.1)707 (4.7)395 (23.8)306 (1.8)Values up to the day of the first positive SARS-CoV-2 test used for training and prediction were considered.

Source: Patient cohort. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning

Study design awaiting verification · Scientific Reports · 2022

Original publication title

Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning

Adrian G. Zucco; Rudi Agius; Rebecka Svanberg; Kasper S. Moestrup; Ramtin Z. Marandi; Cameron Ross MacPherson; Jens Lundgren; Sisse R. Ostrowski; Carsten U. Niemann

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Interpretable risk assessment of SARS-CoV-2 positive patients can aid clinicians to implement precision medicine. Here we trained a machine learning model to predict mortality within 12 weeks of a first positive SARS-CoV-2 test. By leveraging data on 33,938 confirmed SARS-CoV-2 cases in eastern Denmark, we considered 2723 variables extracted from electronic health records (EHR) including demographics, diagnoses, medications, laboratory test results and vital parameters. A discrete-time framework for survival modelling enabled us to predict personalized survival curves and explain individual risk factors.

Performance on the test set was measured with a weighted concordance index of 0.95 and an area under the curve for precision-recall of 0.71. Age, sex, number of medications, previous hospitalizations and lymphocyte counts were identified as top mortality risk factors. Our explainable survival model developed on EHR data also revealed temporal dynamics of the 22 selected risk factors. Upon further validation, this model may allow direct reporting of personalized survival probabilities in routine care.

Authors’ abstract

Interpretable risk assessment of SARS-CoV-2 positive patients can aid clinicians to implement precision medicine. Here we trained a machine learning model to predict mortality within 12 weeks of a first positive SARS-CoV-2 test. By leveraging data on 33,938 confirmed SARS-CoV-2 cases in eastern Denmark, we considered 2723 variables extracted from electronic health records (EHR) including demographics, diagnoses, medications, laboratory test results and vital parameters. A discrete-time framework for survival modelling enabled us to predict personalized survival curves and explain individual risk factors.

Performance on the test set was measured with a weighted concordance index of 0.95 and an area under the curve for precision-recall of 0.71. Age, sex, number of medications, previous hospitalizations and lymphocyte counts were identified as top mortality risk factors. Our explainable survival model developed on EHR data also revealed temporal dynamics of the 22 selected risk factors. Upon further validation, this model may allow direct reporting of personalized survival probabilities in routine care.

Publication and source details

Original title: Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning

Adrian G. Zucco; Rudi Agius; Rebecka Svanberg; Kasper S. Moestrup; Ramtin Z. Marandi; Cameron Ross MacPherson; Jens Lundgren; Sisse R. Ostrowski; Carsten U. Niemann

Scientific Reports · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100001732Danmarks GrundforskningsfondDNRF126http://dx.doi.org/10.13039/100008389Uddannelses: og Forskningsministeriet0238-00006B

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T07:58:41.587083+00:00

DOI: 10.1038/s41598-022-17953-y · PMC9380679